Clopidogrel (SR25990) — Competitive Intelligence Brief

Clopidogrel (SR25990) (Clopidogrel (SR25990)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

phase 3 P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Clopidogrel (SR25990) (Clopidogrel (SR25990)) — Sanofi. Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel (SR25990) TARGET	Clopidogrel (SR25990)	Sanofi	phase 3	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Clopidogrel treatment	Clopidogrel treatment	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

1. Azienda Policlinico Umberto I · 1 drug in this class
2. Hospital Central San Luis Potosi, Mexico · 1 drug in this class
3. Sanofi · 1 drug in this class
4. Seung-Jung Park · 1 drug in this class
5. Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
6. US Department of Veterans Affairs · 1 drug in this class
7. University of Pecs · 1 drug in this class
8. VA Office of Research and Development · 1 drug in this class